RWE 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development

Australia has several real-world evidence (RWE) initiatives to support healthcare and drug development. The Therapeutic Goods Administration (TGA) has established a framework for the use of real-world data (RWD) and RWE in regulatory decision-making, which includes the use of data from electronic health records and disease registries [1]. Following the 2021 Review into the usage of RWE and patient-reported outcomes (PROs) in the regulation of medicines and medical devices, the TGA has been working on incorporating RWE and PROs into its regulatory processes [2][3][4].

Additionally, the Medicines Intelligence Centre of Research Excellence (MI-CRE) was established to generate timely research supporting the evidentiary needs of Australian medicines regulators and payers by accelerating the development and translation of RWE on medicines use and outcomes [4]. MI-CRE aims to equip the next generation of medicines researchers in Australia with the skills to co-create evidence with end-users [5].

Despite these initiatives, there are still challenges and gaps in Australia’s RWE landscape. A review on generating RWE on the quality use, benefits, and safety of medicines in Australia highlights the need for a roadmap to bolster Australia’s capacity to accelerate evidence development about the effectiveness, safety, and quality use of medicines in routine clinical care [6]. Robust RWE generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable healthcare and improve the health and well-being of all Australians [6].

References:

[1] https://globalforum.diaglobal.org/issue/may-2023/rwd-rwe-in-2023-regulatory-policy-world-tour/

[2] https://www.tga.gov.au/real-world-evidence-rwe-and-patient-reported-outcomes-pros

[3] https://www.tga.gov.au/sites/default/files/real-world-evidence-and-patient-reported-outcomes-in-the-regulatory-context.pdf

[4] https://www.sciencedirect.com/science/article/pii/S0149291822000170

[5] https://ijpds.org/article/view/1726

[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707536/

Share this story...
UK – NICE – RWE Framework

October 14, 2023|2023, RWE 201|

RWE 201 - UK – NICE – RWE Framework  NICE RWE Framework: https://www.nice.org.uk/corporate/ecd9/chapter/overviewReal-world data (RWD) encompasses various types of information on patient health, care delivery, and experiences collected outside [...]

UK – MHRA – Randomised Controlled Trials Using Real World Data

October 14, 2023|2023, RWE 201|

RWE 201 - UK – MHRA – Randomised Controlled Trials Using Real World Data   MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions The MHRA guideline focuses on sponsors planning to [...]

UK – MHRA – Use of RWD to Support Regulatory Decisions

October 14, 2023|2023, RWE 201|

RWE 201 - UK – MHRA – Use of RWD to Support Regulatory Decisions   MHRA RWD Guidance: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions The MHRA (Medicines and Healthcare products Regulatory Agency) [...]

Real World Evidence (RWE) 201 – France – Haute Autorité de Santé (HAS) – Real World Study Guide

September 4, 2023|2023, RWE 201|

RWE 201 - France – Haute Autorité de Santé (HAS) – Real World Study Guide  HAS Real World Stidy Guide: https://www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdfThe Haute Autorité de Santé (HAS), France's National Authority [...]